BIIB vs. AEP, NBIX, RGEN, PNW, CRSP, POR, DNLI, GILD, BNTX, and ARGX
Should you be buying Biogen stock or one of its competitors? The main competitors of Biogen include American Electric Power (AEP), Neurocrine Biosciences (NBIX), Repligen (RGEN), Pinnacle West Capital (PNW), CRISPR Therapeutics (CRSP), Portland General Electric (POR), Denali Therapeutics (DNLI), Gilead Sciences (GILD), BioNTech (BNTX), and argenx (ARGX).
American Electric Power (NASDAQ:AEP) and Biogen (NASDAQ:BIIB) are both large-cap utilities companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings, valuation and community ranking.
American Electric Power has higher revenue and earnings than Biogen. American Electric Power is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.
American Electric Power has a net margin of 14.60% compared to American Electric Power's net margin of 12.07%. American Electric Power's return on equity of 14.83% beat Biogen's return on equity.
American Electric Power has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Comparatively, Biogen has a beta of -0.01, meaning that its share price is 101% less volatile than the S&P 500.
In the previous week, Biogen had 5 more articles in the media than American Electric Power. MarketBeat recorded 29 mentions for Biogen and 24 mentions for American Electric Power. Biogen's average media sentiment score of 0.68 beat American Electric Power's score of 0.29 indicating that American Electric Power is being referred to more favorably in the media.
American Electric Power currently has a consensus price target of $88.43, suggesting a potential downside of 4.58%. Biogen has a consensus price target of $288.46, suggesting a potential upside of 25.11%. Given American Electric Power's stronger consensus rating and higher possible upside, analysts plainly believe Biogen is more favorable than American Electric Power.
Biogen received 1698 more outperform votes than American Electric Power when rated by MarketBeat users. Likewise, 71.89% of users gave Biogen an outperform vote while only 55.40% of users gave American Electric Power an outperform vote.
75.2% of American Electric Power shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 0.1% of American Electric Power shares are owned by company insiders. Comparatively, 0.6% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Biogen beats American Electric Power on 13 of the 18 factors compared between the two stocks.
Get Biogen News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BIIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
